Package Leaflet: Information for the User
Irbesartan Zentiva 75 mg film-coated tablets
Irbesartan
Read all of this leaflet carefully before you start taking this medicine because it contains important information for you.
Contents of the pack
Irbesartan Zentiva belongs to a group of medicines called angiotensin-II receptor antagonists. Angiotensin-II is a substance produced in the body that causes blood vessels to constrict, leading to an increase in blood pressure.
Irbesartan Zentiva prevents angiotensin-II from binding to its receptors, relaxing blood vessels and reducing blood pressure. Irbesartan Zentiva slows down the progression of kidney damage in patients with high blood pressure and type 2 diabetes.
Irbesartan Zentiva is used in adult patients
Do not take Irbesartan Zentiva
Warnings and precautions
Consult your doctor before starting to take Irbesartan Zentiva and if any of the following apply to you:
Your doctor may check your kidney function, blood pressure, and blood electrolyte levels (e.g. potassium) at regular intervals.
See also the information under the heading “Do not take Irbesartan Zentiva”.
If you are pregnant, think you might be pregnant, or plan to become pregnant, inform your doctor. Irbesartan Zentiva is not recommended during the first three months of pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby (see section Pregnancy).
Children and adolescents
This medicine should not be used in children and adolescents as the safety and efficacy have not been fully established.
Taking Irbesartan Zentiva with other medicines
Tell your doctor or pharmacist if you are using, have recently used, or might use any other medicines.
Your doctor may need to change your dose and/or take other precautions:
If you are taking an ACE inhibitor or aliskiren (see also the information under the headings “Do not take Irbesartan Zentiva” and “Warnings and precautions”).
You may need to have blood tests if you are taking:
If you are using a type of painkiller called non-steroidal anti-inflammatory medicines, the effect of irbesartan may be reduced.
Taking Irbesartan Zentiva with food and drink
Irbesartan Zentiva can be taken with or without food.
Pregnancy and breastfeeding
Pregnancy
You should inform your doctor if you are pregnant, think you might be pregnant, or plan to become pregnant. Your doctor will normally advise you to stop taking Irbesartan Zentiva before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead. Irbesartan Zentiva should not be taken during the first three months of pregnancy and should not be taken after the third month of pregnancy as it may cause serious harm to your baby.
Breastfeeding
Inform your doctor if you are breastfeeding or about to start breastfeeding as Irbesartan Zentiva is not recommended for use during breastfeeding. Your doctor may decide to give you a different treatment that is more suitable for you, especially if you are breastfeeding a newborn or premature infant.
Driving and using machines
It is unlikely that Irbesartan Zentiva will affect your ability to drive or use machines. However, during treatment of high blood pressure, dizziness or fatigue may occasionally occur. If you experience these symptoms, consult your doctor before driving or using machines.
Irbesartan Zentiva contains lactose. If your doctor has told you that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.
Method of administration
Irbesartan Zentiva is taken orally. The tablets should be swallowed with a sufficient amount of liquid (e.g. one glass of water). Irbesartan Zentiva can be taken with or without food. You should try to take your daily dose at the same time each day. It is important that you continue to take this medicine until your doctor tells you to stop.
The usual dose is 150 mg once daily (two tablets a day). Depending on the response to blood pressure, this dose may be increased to 300 mg once daily (four tablets a day).
In patients with high blood pressure and type 2 diabetes, the recommended maintenance dose for the treatment of kidney disease is 300 mg once daily (four tablets a day). Your doctor may advise a lower dose, especially when starting treatment, in certain patients such as those on hemodialysis or elderly patients over 75 years.
The maximum blood pressure-lowering effect should be achieved within 4-6 weeks after starting treatment.
Use in children and adolescents
Irbesartan Zentiva should not be given to children under 18 years. If a child swallows several tablets, contact your doctor immediately.
If you take more Irbesartan Zentiva than you should
If you accidentally take too many tablets, contact your doctor immediately.
If you forget to take Irbesartan Zentiva
If you accidentally miss a dose, simply take your normal dose when it is due. Do not take a double dose to make up for a forgotten dose.
If you have any further questions on the use of this medicine, ask your doctor or pharmacist.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Some of these side effects can be serious and may need medical attention.
As with similar medicines, rare cases of skin allergic reactions (rash, urticaria) as well as localized swelling of the face, lips, and/or tongue have been reported in patients treated with irbesartan. If you think you have had an allergic reaction, stop taking Irbesartan Zentiva and see a doctor immediately.
The following side effects have been reported:
Very common: may affect more than 1 in 10 people
Common: may affect up to 1 in 10 people
Uncommon: may affect up to 1 in 100 people
The following side effects have been reported in clinical trials:
Since the marketing of Irbesartan Zentiva, the following side effects have been reported:
Frequency not known: cannot be estimated from the available data
The following side effects have been reported: feeling dizzy, headache, altered taste, ringing in the ears, muscle cramps, muscle and joint pain, reduced number of platelets, abnormal liver function, high levels of potassium in the blood, kidney failure, inflammation of small blood vessels, mainly in the skin area (a condition known as leucocytoclastic vasculitis), and severe allergic reactions (anaphylactic shock). Rare cases of jaundice (yellowing of the skin and/or whites of the eyes) have also been reported.
Reporting of side effects
If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the carton after EXP. The expiry date refers to the last day of that month.
Do not store above 30°C.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help protect the environment.
What Irbesartan Zentiva contains
Appearance and packaging
Irbesartan Zentiva 75 mg film-coated tablets are white or almost white, biconvex, and oval-shaped, with a heart-shaped indentation on one side and the number 2871 engraved on the other side.
Irbesartan Zentiva 75 mg film-coated tablets are available in blister packs of 14, 28, 30, 56, 84, 90, or 98 film-coated tablets. They are also available in packs of 56 x 1 film-coated tablet containing unit-dose blisters for hospital use.
Not all pack sizes may be marketed.
Marketing authorisation holder
Zentiva k.s.
U kabelovny 130
102 37 Prague 10
Czech Republic
Manufacturer
SANOFI WINTHROP INDUSTRIE
1, rue de la Vierge
Ambarès & Lagrave
F-33565 Carbon Blanc Cedex - France
SANOFI WINTHROP INDUSTRIE
30-36 Avenue Gustave Eiffel, BP 7166
F-37071 Tours Cedex 2 - France
You can get more information about this medicine by contacting the representative of the marketing authorisation holder.
België/Belgique/Belgien Zentiva, k.s. Tel/Tel: +32 280 86 420 PV-Belgium@zentiva.com | Lietuva Zentiva, k.s. Tel: +370 52152025 PV-Lithuania@zentiva.com |
България Zentiva, k.s. Тел: + 359 2 805 72 08 PV-Bulgaria@zentiva.com | Luxembourg/Luxemburg Zentiva, k.s. Tél/Tel: +352 208 82330 PV-Luxembourg@zentiva.com |
Ceská republika Zentiva, k.s. Tel: +420 267 241 111 PV-Czech-Republic@zentiva.com | Magyarország Zentiva, k.s. Tel.: +36 165 55 722 PV-Hungary@zentiva.com |
Danmark Zentiva, k.s. Tlf: +45 787 68 400 PV-Denmark@zentiva.com | Malta Zentiva, k.s. Tel: +356 277 82 052 PV-Malta@zentiva.com |
Deutschland Zentiva Pharma GmbH Tel: +49 (0) 800 53 53 010 PV-Germany@zentiva.com | Nederland Zentiva, k.s. Tel: +31 202 253 638 PV-Netherlands@zentiva.com |
Eesti Zentiva, k.s. Tel: +372 52 70308 PV-Estonia@zentiva.com | Norge Zentiva, k.s. Tlf: +47 219 66 203 PV-Norway@zentiva.com |
Ελλάδα Zentiva, k.s. Τηλ: +30 211 198 7510 PV-Greece@zentiva.com | Österreich Zentiva, k.s. Tel: +43 720 778 877 PV-Austria@zentiva.com |
España Zentiva, k.s. Tel: +34 931 815 250 PV-Spain@zentiva.com | Polska Zentiva Polska Sp. z o.o. Tel: + 48 22 375 92 00 PV-Poland@zentiva.com |
France Zentiva France Tél: +33 (0) 800 089 219 PV-France@zentiva.com | Portugal Zentiva Portugal, Lda Tel: +351210601360 PV-Portugal@zentiva.com |
Hrvatska Zentiva, k.s. Tel: +385 155 17 772 PV-Croatia@zentiva.com | România S.C. ZENTIVA S.A. Tel: +40 021 317 31 36 PV-Romania@zentiva.com |
Ireland Zentiva, k.s. Tel: +353 766 803 944 PV-Ireland@zentiva.com | Slovenija Zentiva, k.s. Tel: +386 360 00 408 PV-Slovenia@zentiva.com |
Ísland Zentiva, k.s. Sími: +354 539 0650 PV-Iceland@zentiva.com | Slovenská republika Zentiva, a.s. Tel: +421 2 3918 3010 PV-Slovakia@zentiva.com |
Italia Zentiva Italia S.r.l. +39-02-38598801 PV-Italy@zentiva.com | Suomi/Finland Zentiva, k.s. Puh/Tel: +358 942 598 648 PV-Finland@zentiva.com |
Κύπρος Zentiva, k.s. Τηλ: +357 240 30 144 PV-Cyprus@zentiva.com | Sverige Zentiva, k.s. Tel: +46 840 838 822 PV-Sweden@zentiva.com |
Latvija Zentiva, k.s. Tel: +371 67893939 PV-Latvia@zentiva.com | United Kingdom Zentiva Pharma UK Limited Tel: +44 (0) 845 372 7101 PV-United-Kingdom@zentiva.com |
Date of last revision of this leaflet
Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.